RTTNews | Jun 29, 2021 10:29AM EDT

10:28 Tuesday, June 29, 2021 (RTTNews.com) - DiaMedica Therapeutics Inc. (DMAC) shares are sliding more than 31 percent on Tuesday morning trade after the company reported mixed results for the Phase 2 trial of DM199 in patients with chronic kidney disease.

The company reported clinically meaningful improvements in kidney function in Cohorts 1 and 2. However in the third cohort of diabetic kidney disease, the glomerular filtration rate or eGFR and urinary albumin-creatinine ratio or UACR were stable, with a reduction of blood pressure.

The shares of clinical-stage biopharmaceutical company are currently at $4.95, down 31.23 percent from the previous close of $7.17 on a volume of 2,187,775. For the 52-week period, the shares have traded in a range of $4.59-$5.29 on average volume of 103,296.

Read the original article on RTTNews ( https://www.rttnews.com/3205784/diamedica-therapeutics-down-31-on-mixed-results-for-phase-2-trial-of-its-kidney-drug.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved